This paper is only available as a PDF. To read, Please Download here.
Summary
The Merck, Sharp and Dohme hepatitis B vaccine formulated from HBsAg produced by a
recombinant strain of Saccharomyces cerevisiae has proven to be highly immunogenic and safe. A 10 μg dose of the vaccine produced
an anti-HBs response of ⩾ 10 IU/l in 91 % or more of healthy adults who completed
the three-dose regimen. Children responded well to all levels of vaccine antigen utilised
but developed maximum anti-HBs titres with 5 μg doses. The age of the vaccine recipient
affected responsiveness. Younger adults (20–29 years) responded more rapidly and with
higher anti-HBs titres than did older adults (⩾ 50 years). Children responded faster
and with higher anti-HBs levels than younger adults. Clinical reactions reported after
vaccination were mild and transient.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of InfectionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Human hepatitis B vaccine from recombinant yeast.Nature. 1984; 307: 178-180
- Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA.JAMA. 1984; 251: 2812-2815
- Recombinant yeast hepatitis B vaccine: Immunogenicity and safety.Hepatology. 1984; 4: 1077
- Clinical evaluation of a recombinant hepatitis B vaccine.Lancet. 1984; ii: 1174-1175
- Immunogenicity of recombinant yeast hepatitis B vaccine.Lancet. 1985; i: 108-109
- Safety and immunogenicity of a recombinant hepatitis B vaccine.J Med Virol. 1985; 17: 57-62
- Recombinant yeast human hepatitis B vaccine.J Hong Kong Med Assoc. 1985; 37: 75-85
- Immune response after vaccination with recombinant hepatitis B vaccine as compared to that after plasma-derived vaccine.Antiviral Res. 1985; : 273-279
- Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology to yeast.J Infect Dis. 1986; 153: 156-159
- Response to hepatitis B vaccine in a young adult population.in: Szmuness W Alter HJ Maynard JE Viral hepatitis. Franklin Institute Press, Orlando, Florida1982: 451-466
Article info
Identification
Copyright
© 1986 The British Society for the Study of Infection. Published by Elsevier Inc.
